Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing-remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.
Wiendl, H. & Kieseier, B. Nat. Rev. Neurol. 9, 125-126 (2013); published online 29 January 2013; doi:10.1038/nrneurol.2013.2